Ozempic and a sibling treatment called Rybelsus are to thank for that growth
Here is what to look for, starting with visual indicators and then moving to performance-based signs
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility A 104-week carcinogenicity study was conducted in male and female CD-1 mice at doses of 0.03, 0.2, 1.0, and 3.0 mg/kg/day liraglutide administered by bolus subcutaneous injection yielding systemic exposures 0.2-, 2-, 10- and 45-times the human exposure, respectively, at the MRHD of 1.8 mg/day based on plasma AUC comparison
As stated in an article in Scientific American on the lack of racial and ethnic diversity in clinical trials, if diverse groups arent part of these studies, we cant be sure whether the treatment will work in all populations or what side effects might emerge in one group or another. Historically, minority groups and women have been underrepresented in medical studies